Page last updated: 2024-11-10

tricetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tricetin : Flavone hydroxylated at positions 3', 4', 5, 5' and 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281701
CHEMBL ID247484
CHEBI ID507499
SCHEMBL ID158384
MeSH IDM0443939

Synonyms (58)

Synonym
4h-1-benzopyran-4-one, 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-
DIVK1C_006922
SDCCGMLS-0066804.P001
MYF ,
SPECTRUM4_001678
SPECTRUM_001591
SPECTRUM5_000615
BSPBIO_003253
AR-683/41530196
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-chromen-4-one
C10192 ,
5,7,3',4',5'-pentahydroxyflavone
520-31-0
tricetin
NCGC00095682-01
KBIO3_002473
KBIO2_007207
KBIOGR_002235
KBIO2_002071
KBIOSS_002071
KBIO1_001866
KBIO2_004639
SPECTRUM3_001617
SPECTRUM2_000741
SPBIO_000722
SPECPLUS_000826
SPECTRUM1504115
NCGC00178184-01
2O65
5,7,3,4,5-pentahydroxyflavone
bdbm26656
3',4',5,5',7-pentahydroxyflavone
CHEBI:507499 ,
CHEMBL247484
DB08230
LMPK12110847
NCGC00095682-02
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
CCG-40135
hieracin
5627py99zo ,
unii-5627py99zo
BP-10199
SCHEMBL158384
AKOS024287743
ARSRJFRKVXALTF-UHFFFAOYSA-N
DTXSID60199964
SR-05000002560-1
sr-05000002560
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-1-benzopyran-4-one
5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-1-benzopyran-4-one, 9ci
2-(3,4,5-trihydroxyphenyl)-5,7-dihydroxy-4h-1-benzopyran-4-one; pentahydroxyflavone
Q15303946
BRD-K22585547-001-03-3
MS-24353
CS-0137311
HY-131592
Z1980554244

Research Excerpts

Overview

Tricetin is a natural flavonoid derivative that has demonstrated a wide range of therapeutic properties. Tricetin proved to be a good antioxidant but only showed negligible pro-oxidant activity in one of the deoxyribose degradation assay variants.

ExcerptReferenceRelevance
"Tricetin is a natural flavonoid derivative that has demonstrated a wide range of therapeutic properties."( Natural flavone tricetin suppresses oxidized LDL-induced endothelial inflammation mediated by Egr-1.
Cai, L; Gao, F; Hou, M; Zhang, X, 2020
)
1.63
"Tricetin proved to be a good antioxidant but only showed negligible pro-oxidant activity in one of the deoxyribose degradation assay variants."( In Vitro Evaluation of Pro- and Antioxidant Effects of Flavonoid Tricetin in Comparison to Myricetin.
Bachmann, G; Chobot, V; Hadacek, F; Kubicova, L; Weckwerth, W, 2020
)
1.52
"Tricetin is a flavonoid derivative and a potent anti-inflammatory and anticancer agent. "( Tricetin suppresses human oral cancer cell migration by reducing matrix metalloproteinase-9 expression through the mitogen-activated protein kinase signaling pathway.
Chen, MK; Chuang, CY; Chuang, YT; Chung, TT; Hsieh, MJ; Lai, JC; Teng, YH; Yang, SF, 2017
)
3.34
"Tricetin is a dietary flavonoid with cytostatic properties and antimetastatic activities in various solid tumors. "( Tricetin Induces Apoptosis of Human Leukemic HL-60 Cells through a Reactive Oxygen Species-Mediated c-Jun N-Terminal Kinase Activation Pathway.
Chen, HY; Chien, MH; Chow, JM; Hsiao, PC; Lee, WJ; Lin, YW; Tan, P; Wen, YC; Yang, SF, 2017
)
3.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pentahydroxyflavoneA hydroxyflavone substituted by five hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (45)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.89130.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency12.58930.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency12.58930.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency10.00000.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency0.70790.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency17.90080.002014.677939.8107AID1476; AID1478
15-lipoxygenase, partialHomo sapiens (human)Potency2.51190.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency28.18380.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2528
galactokinaseHomo sapiens (human)Potency42.12850.943115.289453.0367AID2015
hemoglobin subunit betaHomo sapiens (human)Potency25.11890.31629.086131.6228AID930
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.78280.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.39810.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1Homo sapiens (human)IC50 (µMol)0.65000.65000.71500.7800AID977608
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1Homo sapiens (human)IC50 (µMol)0.65000.65000.71500.7800AID977608
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1Homo sapiens (human)IC50 (µMol)0.65000.65000.71500.7800AID977608
Chain A, Proto-oncogene serine/threonine-protein kinase Pim-1Homo sapiens (human)IC50 (µMol)0.65000.65000.71500.7800AID977608
Serine/threonine-protein kinase pim-1Homo sapiens (human)IC50 (µMol)0.65000.00040.887110.0000AID1572648; AID1798717
Receptor-type tyrosine-protein phosphatase SHomo sapiens (human)IC50 (µMol)17.50000.60002.45004.3000AID1265972
Sialidase-2Homo sapiens (human)IC50 (µMol)130.00003.90006.73337.8000AID466938
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase pim-1Homo sapiens (human)-Log IC500.19000.01000.17860.4700AID311148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of neuron projection developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
spinal cord developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
cerebellum developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
hippocampus developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
cerebral cortex developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
corpus callosum developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of axon extensionReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of interferon-alpha productionReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of interferon-beta productionReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of toll-like receptor 9 signaling pathwayReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of collateral sproutingReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of axon regenerationReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
modulation of chemical synaptic transmissionReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
negative regulation of dendritic spine developmentReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
establishment of endothelial intestinal barrierReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
regulation of postsynaptic density assemblyReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
trans-synaptic signalingReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
synaptic membrane adhesionReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
glycoprotein catabolic processSialidase-2Homo sapiens (human)
ganglioside catabolic processSialidase-2Homo sapiens (human)
oligosaccharide catabolic processSialidase-2Homo sapiens (human)
glycosphingolipid catabolic processSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
phosphoprotein phosphatase activityReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
heparin bindingReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
chondroitin sulfate bindingReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
heparan sulfate proteoglycan bindingReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
exo-alpha-sialidase activitySialidase-2Homo sapiens (human)
protein bindingSialidase-2Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
plasma membraneReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
axonReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
growth coneReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
synaptic vesicle membraneReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
presynaptic membraneReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
perikaryonReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
Schaffer collateral - CA1 synapseReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
postsynaptic density membraneReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
glutamatergic synapseReceptor-type tyrosine-protein phosphatase SHomo sapiens (human)
cytosolSialidase-2Homo sapiens (human)
catalytic complexSialidase-2Homo sapiens (human)
lysosomeSialidase-2Homo sapiens (human)
membraneSialidase-2Homo sapiens (human)
cytoplasmSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID658253Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID761447Inhibition of NOX2 in human THP1 cells assessed as suppression of TPA-induced membrane translocation of p47phox at 20 uM incubated for 1 hr prior to TPA challenge measured after 12 hrs by Western blot analysis2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID761455Inhibition of NOX2 in human THP1 cells assessed as downregulation of TPA-induced CD36 mRNA expression at 20 uM incubated for 1 hr prior to TPA challenge measured after 24 hrs by RT-PCR analysis2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox.
AID501209Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Phloroglucinol glycosides from the fresh fruits of Eucalyptus maideni.
AID1264945Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 1 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264969Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 98%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID658255Cytotoxicity against human Huh7.5.1 cells by MTT assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID466939Selectivity for Trypanosoma cruzi trans-sialidase mutant over human Neu22010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID761448Downregulation of TPA-induced NOX2 mRNA expression in human THP1 cells at 20 uM incubated for 1 hr prior to TPA challenge measured after 24 hrs by RT-PCR analysis2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox.
AID1264959Decrease in ALP activity in human MSC using p-NPP as substrate at 5 uM after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1434690Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relat2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
AID1264968Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 98%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID501210Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay2010Journal of natural products, Feb-26, Volume: 73, Issue:2
Phloroglucinol glycosides from the fresh fruits of Eucalyptus maideni.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1264963Cytotoxicity against human MSC assessed as cell viability at 5 uM after 24 hrs measured on day 1 by alamar blue assay (Rvb = 102 +/- 1%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264971Cytotoxicity against human MSC assessed as decrease in cell number at 10 uM after 9 days by methylene blue staining based microscopy relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264967Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 100 +/- 1%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID466938Inhibition of human Neu2 assessed as MuNANA substrate hydrolysis in presence of 0.1% Triton X-100 by discontinuous fluorimetric assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID761456Inhibition of NOX2 in human THP1 cells assessed as downregulation of TPA-induced CD14 mRNA expression at 20 uM incubated for 1 hr prior to TPA challenge measured after 24 hrs by RT-PCR analysis2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox.
AID1264965Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 100 +/- 1%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1265972Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Identification of novel protein tyrosine phosphatase sigma inhibitors promoting neurite extension.
AID1264970Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 98%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264966Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 100 +/- 1%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID474216Inhibition of FCepsilonRI expression in human HMC1 cells at 50 to 100 uM after 72 hrs by flow cytometry2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
New inhibitors for expression of IgE receptor on human mast cell.
AID1264960Decrease in ALP activity in human MSC using p-NPP as substrate at 10 uM after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1572648Inhibition of recombinant PIM1 (unknown origin) expressed in Escherichia coli after 60 mins by ELISA2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.
AID1264972Cytotoxicity against human MSC assessed as decrease in cell number at 5 uM after 9 days by methylene blue staining based microscopy relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID761457Inhibition of NOX2 in human THP1 cells assessed as downregulation of TPA-induced CD11b mRNA expression at 20 uM incubated for 1 hr prior to TPA challenge measured after 24 hrs by RT-PCR analysis2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox.
AID502292Antioxidant activity assessed as DDPH radical scavenging activity2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Relationships between structures of hydroxyflavones and their antioxidative effects.
AID311148Inhibition of PIM1 kinase2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
AID1264964Cytotoxicity against human MSC assessed as cell viability at 10 uM after 24 hrs measured on day 1 by alamar blue assay (Rvb = 102 +/- 1%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264962Cytotoxicity against human MSC assessed as cell viability at 1 uM measured on day 1 by alamar blue assay (Rvb = 102 +/- 1%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID761451Inhibition of NOX2 in human THP1 cells assessed as suppression of TPA-induced cell adhesion at 20 uM incubated for 1 hr prior to TPA challenge measured after 24 hrs by microscopic analysis2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Luteolin suppresses the differentiation of THP-1 cells through the Inhibition of NOX2 mRNA expression and the membrane translocation of p47phox.
AID466937Inhibition of Trypanosoma cruzi trans-sialidase containing catalytic domain (N58F, R200K) and lectin-like domain (S495 K, V496G, E520K, D593G, I597D, H599R) mutation expressed in Escherichia coli JM109 assessed as MuNANA substrate hydrolysis in presence o2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID1265971Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate at 20 uM for 60 mins by fluorescence analysis2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Identification of novel protein tyrosine phosphatase sigma inhibitors promoting neurite extension.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2007Molecular cancer therapeutics, Jan, Volume: 6, Issue:1
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2007Molecular cancer therapeutics, Jan, Volume: 6, Issue:1
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
AID1798717Solid-Phase ELISA Kinase Assay from Article 10.1158/1535-7163.MCT-06-0397: \\Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.\\2007Molecular cancer therapeutics, Jan, Volume: 6, Issue:1
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (22.50)29.6817
2010's25 (62.50)24.3611
2020's6 (15.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.64 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (95.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]